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ABSTRACT 
It has been hypothesized that respiration defects caused by accumulation of 
pathogenic mitochondrial DNA (mtDNA) mutations and the resultant overproduction 
of reactive oxygen species (ROS) or lactates are responsible for aging and age-
associated disorders, including diabetes and tumor development. However, there is no 
direct evidence to prove the involvement of mtDNA mutations in these processes, 
because it is difficult to exclude the possible involvement of nuclear DNA mutations. 
Our previous studies resolved this issue by using an mtDNA exchange technology and 
showed that a G13997A mtDNA mutation found in mouse tumor cells induces 
metastasis via ROS overproduction. Here, using transmitochondrial mice (mito-mice), 
which we had generated previously by introducing G13997A mtDNA from mouse 
tumor cells into mouse embryonic stem cells, we provide convincing evidence 
supporting part of the abovementioned hypothesis by showing that G13997A mtDNA 
regulates diabetes development, lymphoma formation, and metastasis—but not 
aging—in this model. 
 
INTRODUCTION 
Pathogenic mtDNA mutations that induce significant mitochondrial respiration defects are 
responsible for mitochondrial diseases (1, 2) and could also be involved in aging and age-
associated disorders, including tumor development (1–5). On the other hand, mitochondrial 
respiration defects caused by nuclear DNA mutations and the resultant enhanced glycolysis 
under normoxic conditions, i.e., the Warburg effect, are proposed to be involved in tumor 
development (6–9). Because pathogenic mtDNA mutations also induce mitochondrial 
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respiration defects and upregulation of aerobic glycolysis, accumulation of these mtDNA 
mutations with age could also be responsible for tumor development. In addition, it is 
possible that mtDNA mutations regulate tumor development as a consequence of 
overproduction of reactive oxygen species (ROS) and the resultant induction of genetic 
instability (1, 2, 10). In fact, somatic mtDNA mutations are preferentially accumulated in 
human tumor cells (11–13), and a germline mtDNA mutation (A8344G) in the tRNALys 
gene has been found in lipomas (benign adipose tissue tumors) (14). However, there is as 
yet no direct evidence for the contribution of mtDNA mutations to aging and tumor 
development, because of the difficulty of excluding the possible contribution of nuclear 
DNA mutations, including copy number variants (CNVs), to these processes (2, 15). 
Our previous study (16) resolved this issue by using complete mtDNA exchange 
technology between mouse normal and tumor cells, and we showed that exogenously 
introduced mtDNA does not affect tumorigenicity. In contrast, our recent study (17) 
performed exchange of mtDNA between poorly and highly metastatic mouse tumor cells, 
providing convincing evidence that the somatic mtDNA mutation G13997A in the ND6 
gene, which encodes one of the subunits of respiration complex I (NADH dehydrogenase), 
reversibly controls the development of highly metastatic potential in tumor cells. Moreover, 
the induction of metastasis is due to overproduction of ROS (17) but not to overproduction 
of lactates (18). However, these studies have not answered the questions of whether the 
mutated mtDNA actually controls metastatic phenotypes in living mice and whether it also 
controls aging and age-associated disorders, including tumor development. Because it is not 
possible to examine these questions as far as the mutated mtDNA is confined in tumor cells, 
we performed intercellular transfer of G13997A mtDNA from highly metastatic tumor cells 
into mouse embryonic stem cells, and generated transmitochondrial mito-mice possessing 
only G13997A mtDNA (19). 
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This study used aged inbred C57BL/6J (B6) mice and age-matched mito-mice (named 
mito-miceND6M), which carry G13997A mtDNA but share the B6 nuclear background to 
exclude the possible involvement of nuclear DNA variations in the phenotypes exclusively 
developed in aged mito-miceND6M. We examined whether aged mito-miceND6M with 
G13997A mtDNA introduced from the highly metastatic tumor cells would be susceptible 
to aging and to age-associated disorders such as tumor development. 
 
Results 
Mitochondrial Disease Phenotypes in Aged Mito-miceND6M. Using the aged 
transmitochondrial mito-miceND6M, we first examined whether aging enhances respiration 
defects and the phenotypes associated with mitochondrial diseases. Complex I activity in 
the tissues of aged mito-miceND6M (18-month-old males) was about 35% to 40% lower 
than that in age-matched B6 males (Fig. 1A). In aged mito-miceND6M, ROS were 
overproduced in bone marrow cells but not in splenocytes (Fig. 1B). Considering that 
young mito-miceND6M (3-month-old males) show a 30% reduction in complex I activity 
and no ROS overproduction (19), aging enhanced these phenotypes. 
Our previous study (19) also showed that young mito-miceND6M (3-month-old males) have 
slight lactic acidosis, a common phenotype in humans with mitochondrial diseases (1, 2) 
and in mito-mice with other pathogenic mtDNA mutations (20–22). Using aged mito-
miceND6M (21-month-old males), this study reexamined blood lactate levels. We also used 
mito-miceCOIM, which we had generated previously (21), as positive controls with lactic 
acidosis due to respiration complex IV defects caused by a pathogenic T6589C mtDNA 
mutation in the COI gene. Unlike B6 mice, both aged mito-miceND6M and age-matched 
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mito-miceCOIM (21-month-old males) had slight lactic acidosis in the peripheral blood (Fig. 
1C). Induction of lactic acidosis, i.e., the Warburg effect, was therefore common to the two 
mutants (mito-miceND6M and mito-miceCOIM), irrespective of whether they were young or 
aged or whether they express respiration defects in complex I or IV activity. 
In addition to lactic acidosis, aged patients with mitochondrial diseases sometimes express 
diabetes, which is one of the age-associated disorders considered to be caused by mtDNA 
mutations (1, 2). We therefore examined blood glucose and insulin levels. Although we 
found no significant differences in blood insulin levels between aged mito-miceND6M (21-
month-old males) and age-matched B6 males (Fig. S1), aged mito-miceND6M had higher 
blood glucose levels after glucose stimulation than did age-matched B6 mice; however, 
glucose levels in aged mito-miceCOIM did not differ from those in age-matched B6 mice 
(Fig. 1D). Therefore, all pathogenic mtDNA mutations, inducing mitochondrial respiration 
defects, do not necessarily cause mitochondrial diabetes. Because the G13997A mutation, 
but not the T6589C mutation, induces ROS overproduction (17), the increased glucose 
levels observed exclusively in aged mito-miceND6M might have resulted not from lactate 
overproduction but from ROS overproduction. This idea was supported by the results of 
administration of N-acetylcysteine (NAC), an antioxidant, to the mito-miceND6M: NAC 
treatment for 1 week suppressed the glucose intolerance (Fig. S2). 
Lifespan and Tumor Formation Frequency in Mito-MiceND6M. Respiration 
defects caused by mtDNA mutations and the resultant overproduction of ROS and lactates 
are also considered to induce aging and age-associated disorders, including tumor 
formation (1–4, 6–13, 23, 24). We therefore examined this hypothesis by using 35 mito-
miceND6M males and 35 B6 males. We also examined 18 mito-miceCOIM males as 
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controls expressing lactic acidosis (Fig. 1C) to test whether the lactic acidosis common to 
mito-miceND6M and mito-miceCOIM would affect lifespan and tumor formation frequency. 
Median survival times of mito-miceND6M, B6 mice, and mito-miceCOIM were 24.6, 26.1, 
and 26.6 months, respectively. Although mito-miceND6M had slightly shorter survival 
times than B6 mice, the difference was not significant (Fig. 2A). No leukemic cells were 
present in the peripheral blood throughout the lifespans of B6 and mutant mice. However, 
gross necropsy of all dead or euthanized moribund mice showed that 16 of 35 mito-
miceND6M (45.7%) had macroscopic tumor-like abnormalities, including enlarged spleen 
and liver and lymph node tumors (Table 1 and Fig. 3A); similar abnormalities were 
observed in only three of 35 B6 mice (8.6%) and one of 18 mito-miceCOIM (5.6%). The 
median survival times of mice without tumor-like abnormalities were 25.3 (mito-
miceND6M), 26.0 (B6 mice), and 26.6 months (mito-miceCOIM); these differences were not 
significant (Fig. 2B). The slightly shorter median survival times of mito-miceND6M 
compared with those of B6 mice (Fig. 2A) were therefore at least partly due to the higher 
frequency of abnormal-tissue formation in aged mito-miceND6M than in age-matched B6 
mice (Table 1). 
Histological analyses of abnormal tissues revealed that all were hematopoietic neoplasms 
and were positive for the pan-leukocyte marker CD45 (Table 1 and Fig. 3B). As no 
leukemic cells were observed in the peripheral blood (Fig. 3A), these hematological 
neoplasms may have consisted of lymphoma cells. Most tumors were of B-cell origin, 
expressing the B-cell marker B220 (CD45R) (Fig. 3B); they were either follicular 
lymphoma or diffuse large B-cell lymphoma arising in the spleen, liver, or lung (Table 1). 
One aged mito-miceND6M male and one aged B6 male developed T-cell lymphoma, 
staining positive for the T-cell marker CD3 (Table 1). These data indicated that mito-
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miceND6M were 750% more prone to lymphoma development than B6 mice in a B cell–
specific manner, providing unambiguous evidence supporting the hypothesis that 
mitochondrial respiration defects are responsible for tumor formation. However, respiration 
defects and the resultant lactic acidosis alone could not have been responsible for the 
frequent B-cell lymphoma formation in the mito-miceND6M, because aged mito-miceCOIM, 
which also showed respiration defects and resultant lactic acidosis (Fig. 1C), did not have 
high frequencies of lymphoma formation (Table 1). It is therefore likely that the ROS 
overproduction in the bone marrow of mito-miceND6M (Fig. 1B) is crucial for B-cell 
lymphoma formation. Analysis of the CNVs showed partial gains of chromosomes 3 and 11 
in the spleen with B-cell lymphoma from a mito-mouseND6M (Fig. S3), suggesting that 
G13997A mtDNA and the resultant ROS overproduction and chromosome aberration are 
involved in B-cell lymphoma development. 
Metastatic Potential in Mito-miceND6M. Mito-miceND6M did not form tumors other 
than lymphomas during their lifespans (Table 1). Thus, the tumor-inducing effect of 
G13997A mtDNA might be restricted to lymphoma formation, and it might therefore be 
difficult to examine the effects of G13997 mtDNA on metastatic potential in mito-
miceND6M. We examined these possibilities by isolating mouse embryonic fibroblasts 
(MEFs) and testing whether G13997A mtDNA affected their tumor-related phenotypes, 
such as immortalization of MEFs to lose their finite lifespan, transformation of 
immortalized MEFs to acquire tumorigenicity, or malignant progression of the transformed 
MEFs to express metastasis. 
We obtained three MEF lines (MEFB6-I, -II, -III) from three B6 embryos and four lines 
(MEFND6M-I, -II, -III, -IV) from four mito-miceND6M embryos (Table S1). By culturing 
these seven MEF lines using the 3T3 protocol (25, 26; see Methods), we isolated six 
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immortalized 3T3 lines (3T3B6-I, -II, -III; 3T3ND6M-I, -II, -III); we failed to obtain one 
3T3 line from an MEF line (MEFND6M-IV) with G13997A mtDNA (Table S1). The 
average numbers of cell divisions for the MEF lines to lose their finite lifespan were 7.9 for 
MEFB6 and 11.0 for MEFND6M (Fig. 4A), suggesting that at least three additional cell 
divisions were required for immortality in MEFND6M with G13997A mtDNA. Therefore, 
G13997A mtDNA does not enhance, but instead slightly suppresses, immortalization in 
MEFs. 
Next, we examined the frequency of spontaneous transformation of immortalized 3T3 lines 
into tumor cells expressing tumorigenicity. After we had established six immortal 3T3 lines, 
we cultured them for 1 month to obtain sufficient numbers of cells for inoculation to test 
their tumorigenicity. After inoculating the cells subcutaneously into the backs of B6 mice, 
we observed growing tumor masses only from the inoculation of two 3T3 lines, 3T3B6-III 
and 3T3ND6M-I, carrying B6 mtDNA and G13997A mtDNA, respectively; the other four 
3T3 lines did not form tumor masses (Fig. 4B). These four non-transformed 3T3 lines were 
cultured for 3 months more to allow spontaneous transformation. They were then 
inoculated again subcutaneously into the backs of B6 mice. Two 3T3 lines, 3T3B6-II and 
3T3ND6M-III, formed tumors (Fig. 4B), probably because of their spontaneous 
transformation to acquire tumorigenicity during prolonged cultivation. These observations 
suggest that some of the cells in the populations of the four immortal 3T3 lines had already 
been transformed spontaneously, and that G13997A mtDNA did not necessarily enhance 
the transformation frequency of immortalized 3T3 cells to acquire tumorigenicity. 
To purify the transformed cells in the population of the four 3T3 line, tumor masses formed 
from the inoculations under the skin of B6 mice (Fig. 4B) were cut into small pieces and 
placed back into culture medium. Growing cells in culture were obtained from all tumor 
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masses. These cells were then inoculated again subcutaneously into the backs of B6 mice. 
All of them rapidly formed tumor masses (Fig. 4C), suggesting that they were fibrosarcoma 
lines expressing tumorigenicity. The lines were named FSB6-II, FSB6-III, FSND6M-I, and 
FSND6M-III (Table S1).  FSB6-II and FSB6-III were confirmed to possess wild-type (B6) 
mtDNA, and FSND6M-I and FSND6M-III possessed G13997A mtDNA (Fig. 4D). 
We then examined the metastatic potential of the fibrosarcoma lines by inoculating them 
intravenously into B6 mice and counting nodule numbers in the lung. This malignant tumor 
phenotype was exclusively enhanced in the fibrosarcoma cell lines FSND6M-I and -III (Fig. 
4E), which carried G13997A mtDNA (Fig. 4D), even though their primary tumor growth 
was slower than that of FSB6-II and -III (Fig. 4C), which had B6 mtDNA (Fig. 4D). 
Therefore, G13997A mtDNA did not enhance immortalization and transformation of MEFs, 
but it enhanced the malignant progression of spontaneously-transformed MEFs to acquire 
high metastatic potential. 
 
Discussion 
Here, we used aged mito-miceND6M with pathogenic G13997A mtDNA to examine 
conventional mitochondrial theory (1–5) proposing that respiration defects caused by 
pathogenic mtDNA mutations and the resultant ROS or lactate overproduction are 
responsible for aging and age-associated disorders. As controls we used age-matched B6 
mice with normal mtDNA and mito-miceCOIM mice with pathogenic T6589C mtDNA (21), 
which induces respiration defects and the resultant lactate overproduction but not ROS 
overproduction (17). All of the mice used in this study shared the B6 nuclear DNA 
background, thus excluding the possible involvement of nuclear genetic variations in the 
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phenotypes exclusively developed in mito-miceND6M. The results showed that neither 
G13997A mtDNA nor T6589C mtDNA enhanced aging, but that G13997A mtDNA 
induced B-lymphoma formation and glucose intolerance, whereas T6589C mtDNA did not. 
Therefore, this study provides convincing evidence that some pathogenic mtDNA 
mutations, such as the G13997A mutation, regulate age-associated disorders, including B-
lymphoma development and diabetes, in living mice. Moreover, G13997A mtDNA 
appeared to play various roles in the multiple steps required for MEF transformation. For 
example, G13997A mtDNA slightly suppressed immortalization of MEFs to loose their 
finite lifespan (Fig. 4A), and it did not induce transformation of immortalized MEFs to 
acquire tumorigenicity (Fig. 4B). However, it did induce malignant progression of the 
transformed MEFs to express high metastatic potential (Fig. 4E). These results are 
consistent with our previous observations (17): using an in vitro culture system we 
previously showed that the G13997A mutation induced malignant progression of lung 
carcinoma cells to acquire high metastatic potential, but it did not induce transformation of 
immortalized NIH3T3 cells to acquire tumorigenicity (17). Therefore, our finding here that 
the mutation induced frequent B-lymphoma development in mito-miceND6M (Table 1) was 
unexpected.  
The question that then arises is why were there only hematological malignancies (Table 1) 
despite the fact that respiration defects affected all of the tissues examined (Fig. 1A). One 
answer to this tissue-specific tumor development is that the nuclear genetic background of 
the B6 mice used in this study made them prone to B-lymphoma formation but not to other 
tumors during their lifespans (Table 1). This idea can be examined by generating mito-
miceND6M carrying G13997A mtDNA but in a nuclear genetic background derived from 
another wild-type mouse strain that preferentially develops tumors other than B-lymphoma. 
It has been proposed that nuclear genetic variations among wild-type mouse strains affect 
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the tumor formation spectrum (27-30), particularly when genetic manipulations are 
performed to induce tumor development (29, 30). Thus the generation of new mito-
miceND6M would be effective for examining the issue of whether G13997A mtDNA 
enhances the development of different tumors in different nuclear genetic backgrounds, or 
whether it specifically enhances B-lymphoma development irrespective of whether the 
nuclear genetic background is derived from B6 or not. 
Another question is the nature of the mechanism of B-lymphoma development in mito-
miceND6M. Analysis of CNVs showed partial gains of chromosomes 3 and 11 in a spleen 
with B-lymphoma from a mito-mouseND6M (Fig. S3). Thus, one possible mechanism could 
be chromosomal instability caused by G13997A mtDNA–mediated overproduction of ROS. 
It has been proposed that oxidative stress induces various types of cellular damage, leading 
to chromosome instability that can result in tumor development (10). Moreover, B-
lymphomas can be frequently induced as a consequence of chromosome translocation (31). 
Precise chromosome analysis may therefore reveal the mechanism of frequent B-lymphoma 
formation in mito-miceND6M. 
With respect to the aging of mito-miceND6M, the G13997A mutation does not solely 
enhance aging or regulate premature aging phenotypes, which have been reported in 
mtDNA mutator mice possessing nuclear-coded mtDNA polymerase with a defective 
proofreading function and expressing the resultant mitochondrial respiration defects but not 
ROS overproduction (32-34). Absence of the premature aging phenotypes in mito-
miceND6M is not unexpected, because there is no evidence that patients with mitochondrial 
diseases due to pathogenic mtDNA mutations develop generalized premature aging. 
Therefore, the introduction of different nuclear genetic backgrounds or nuclear DNA 
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variations into mito-miceND6M may be required to trigger the onset of their premature 
aging phenotypes.  
Our results also suggested that the glucose intolerance observed exclusively in aged mito-
miceND6M (Fig. 1D) resulted from ROS overproduction. This idea was confirmed by the 
observation that NAC administration suppressed glucose intolerance (Fig. S2). Continuous 
NAC administration could therefore be an effective therapy for improving ROS-mediated 
diabetic phenotypes. Because it has been proposed that ROS negatively controls insulin 
secretion from pancreatic β cells or glucose incorporation into insulin-targeted organs in 
humans (35), mito-miceND6M would be effective models for precise investigation of the 
mechanisms of ROS-mediated diabetes. On the other hand, a reduction in ATP content 
caused by mitochondrial respiration defects in pancreatic β cells has also been proposed to 
suppress their insulin secretion and could thus be responsible for inducing mitochondrial 
diabetes (36). In fact, patients with mitochondrial diseases who carry an A3243G mtDNA 
mutation in the mitochondrial tRNALeu(UUR) gene frequently express diabetic phenotypes (1, 
35, 37). However, other pathogenic mtDNA mutations are not necessarily correlated with 
these phenotypes (37). Our mito-miceCOIM did not show glucose intolerance (Fig. 1D), 
indicating that respiration defects do not always induce diabetic phenotypes. Other mito-
mice carrying a pathogenic mutation in the mitochondrial tRNALeu(UUR) gene will therefore 
have to be generated to resolve this controversy over the pathogenesis of mitochondrial 
diabetes. 
 
Materials and Methods 
Mice. Inbred B6 mice generated by sibling mating more than 40 times were obtained from 
CLEA Japan. Mito-miceND6M (19) and mito-miceCOIM (21) were generated in our 
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previous works. We maintained B6 mice, mito-miceND6M, and mito-miceCOIM sharing a 
common nuclear DNA background by repeated backcrossing of their females with B6 
males. Animal experiments were performed in accordance with protocols approved by the 
Experimental Animal Committee of the University of Tsukuba, Japan. 
Cell Lines and Cell Culture. The mouse cell lines obtained were grown in DMEM 
(Sigma) containing 10% (vol/vol) FCS, uridine (50 ng/ml), and pyruvate (0.1 mg/ml). 
Biochemical Measurement of Respiratory Enzyme Activity. Mitochondrial 
respiratory complex I (NADH dehydrogenase), complex II (succinate dehydrogenase), and 
complex III (cytochrome c reductase) are components of the electron-transport chain and 
are located in the mitochondrial inner membrane. The activity of these enzymes was 
assayed as described previously (11). Briefly, to estimate complex I + III activity, NADH 
and cytochrome c (oxidized form) were used as substrates and the reduction of cytochrome 
c was monitored by measuring absorbance at a wavelength of 550 nm. To estimate complex 
II + III activity, sodium succinate and cytochrome c (oxidized form) were used as 
substrates, and the reduction of cytochrome c was monitored as described above. 
Measurement of ROS Production in Mitochondria. ROS generation was detected 
with the mitochondrial superoxide indicator MitoSOX-Red (Invitrogen). Cells were 
incubated with 1 mM MitoSOX-Red for 15 min at 37 ºC in phosphate-buffered saline 
(PBS), washed twice with PBS, and then immediately analyzed with a FACScan flow 
cytometer (Becton Dickinson). 
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Lactate and Glucose Measurement. To determine fasting blood lactate and glucose 
concentrations, blood was collected from the tail veins of mice after overnight starvation. 
After oral administration of glucose (1.5 g/kg body weight), blood was again collected, and 
lactate and glucose concentrations were measured with an automatic blood lactate test 
meter (Lactate Pro, Arkray) and glucose test meter (Dexter ZII, Bayer), respectively. 
Blood Insulin Measurement. Peripheral bloods were collected from tail veins. After 
centrifugation of the blood at 1000g for 15 min at 4 ºC, the plasma fraction collected from 
the supernatant was used to estimate blood insulin levels with a mouse insulin ELISA kit 
(Shibayagi). 
Histological Analyses. Formalin-fixed, paraffin-embedded serial sections were used for 
histological analyses. Hematoxylin and eosin–stained sections were used for 
histopathological analysis to identify tumor tissues. The immunohistochemical analysis was 
performed with antibody to CD45 (BD Biosciences) to determine whether the tumor tissues 
originated from leukocytes, and subsequently with antibodies to B220 (BD Biosciences) 
and CD3 (Santa Cruz) to determine whether the tumor tissues were of B-cell or T-cell 
origin, respectively. 
Analysis of CNVs. Copy number variations in nuclear DNA were examined by array 
CGH (comparative genomic hybridization) using a 4×44k whole-genome array (Agilent 
Technologies G4426B#15028). DNA (1 µg) derived from each male mouse spleen was 
used. A dye-swap experiment was conducted to confirm the results. The protocol for DNA 
digestion, labeling, purification, and hybridization to the arrays followed the 
manufacturers’ instructions (Agilent Technologies). 
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Isolation of Immortal 3T3 Cells from MEFs. MEFs in a 6-cm culture dish at a density 
of 3×105 cells per dish were cultured by using the 3T3 protocol reported previously (25, 26). 
Briefly, 3 days after the cells had been plated at 3×105 cells per dish, we trypsinized them, 
counted the total cell numbers, and then replated 3×105 cells into 6-cm dishes. These 
processes were repeated until immortalized cells appeared. 
Genotyping of mtDNAs. Total cellular DNA (0.2 mg) extracted from cultured cells was 
used as a template. To detect the G13997A mutation, a 147-bp fragment containing the 
13997 site was amplified by using PCR. The nucleotide sequences from nucleotide 
positions 13963 to 13996 (5′-CCCACTAACAATTAAACCTAAACCTCCATActTA-3′; 
small letters indicate the mismatch site) and nucleotide positions 14109 to 14076 (5′-
TTCATGTCATTGGTCGCAGTTGAATGCTGTGTAG-3′) were used as oligonucleotide 
primers. Combination of the PCR-generated mutation with the G13997A mutation created a 
restriction site for Afl II and generated 114-bp and 33-bp fragments on Afl II digestion. 
Restriction fragments were separated by electrophoresis on 3% agarose gels containing 
ethidium bromide (0.1 mg/ml). 
Assays of Metastatic Potential and Tumorigenicity. To test for experimental 
metastatic potential, cells (5×105/100 µl PBS) were injected into the tail vein of 6-week-old 
male B6 mice (CLEA Japan). The mice were euthanized 23 days later, and their lungs were 
removed. The lungs were fixed in Bouin’s solution and parietal nodules were counted. To 
assess tumorigenicity, growing cells (5×106 cells) suspended in 100 µl PBS were injected 
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subcutaneously into the backs of 5 week-old male B6 mice. Tumor growth was monitored 
assuming spherical growth. When a tumor mass was detectable visually, its maximum (a) 
and minimum (b) diameters and height (h) were recorded twice a week. The volume of 
each tumor (V) was calculated according to the formula V = πabh/6. 
Statistical Analysis. We analyzed data with the (unpaired or paired) Student’s t-test. 
Kaplan–Meier curves were assessed with the log-rank test. Values with P < 0.05 were 
considered significant. 
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FIGURE LEGENDS 
Fig. 1. Examination of the phenotypes associated with mitochondrial diseases in 
aged mito-miceND6M. 
(A) Biochemical analysis of mitochondrial respiratory complex activity in the brain, 
heart, and skeletal muscles. Respiratory complex I (NADH dehydrogenase), 
complex II (succinate dehydrogenase), and complex III (cytochrome c reductase) 
are components of the electron-transport chain located in the mitochondrial inner 
membrane. Because the activity of complexes II + III is normal in the tissues of 
mito-miceND6M, the reduced activity of complexes I + III observed in mito-
miceND6M should represent complex I defects. Data are represented as mean 
values with SD (n = 3). *P < 0.05 compared with control B6 mice. (B) Estimation of 
mitochondrial superoxide (i.e., reactive oxygen species, ROS) levels in bone 
marrow cells and splenocytes after treatment with MitoSOX-Red (Invitrogen). 
Relative mitochondrial superoxide levels were expressed as mean fluorescence 
intensity. Data are represented as mean values with SD (n = 3). *P < 0.05 
compared with control B6 mice. (C) Estimation of blood lactate levels in aged mito-
miceND6M, age-matched B6 mice, and age-matched mito-miceCOIM before and 
after glucose administration. Data are represented as mean values with SD (n = 5). 
*P < 0.05 compared with control B6 mice. (D) Estimation of blood glucose levels in 
aged mito-miceND6M, age-matched B6 mice, and age-matched mito-miceCOIM 
before and after glucose administration. Data are represented as mean values with 
SD (n = 5). *P < 0.05 compared with control B6 mice. 
 
Fig. 2. Kaplan–Meier survival curves of mito-miceND6M. 
(A) Comparison of lifespan of mice. Median survival times of mito-miceND6M (n = 
35), B6 mice (n = 35), and mito-miceCOIM (n = 18) were 24.6, 26.1, and 26.6 
months, respectively. Survival curves did not differ significantly. (B) Comparison of 
lifespans of mice that died in the absence of detectable B-cell lymphoma. Median 
survival times of mito-miceND6M (n = 19), B6 mice (n = 32), and mito-miceCOIM (n 
22 
= 17) were 25.3, 26.0, and 26.6 months, respectively. Survival curves did not differ 
significantly. 
 
Fig. 3. B-cell lymphoma formation in the tissues of aged mito-miceND6M. 
(A) Gross necropsy of euthanized moribund mice, smear samples of peripheral 
blood stained by Giemsa, and tissues. Left and right panels represent a euthanized 
moribund B6 mouse without tumors (B6-3) and a euthanized moribund mito-
mouseND6M with tumors (ND6M -6), respectively. Scale bars, 1 cm. 
Giemsa-stained preparations show the absence of leukemic cells in the peripheral 
blood of both B6-3 and ND6M-6. Scale bars, 50 µm. (B) Histological analyses of 
serial sections of the tissues to identify B-cell lymphoma. HE, hematoxylin and 
eosin staining to show tumor formation; CD45, immunohistochemistry using 
antibody to CD45 to detect leukocytes; B220, immunohistochemistry using 
antibody to B220 to detect B cells; CD3, immunohistochemistry using antibody to 
CD3 to detect T cells. Whereas the tissues of B6-3 have a normal structure (left 
panels), those of ND6M-6 show abnormal growth of B-lymphoma cells, because 
they were stained positively with CD45 and B220, but not with CD3 (right panels). 
The spleen was the primary B-lymphoma site, whereas the liver and lung were 
secondarily involved through hematogenous metastasis: most of the splenic 
parenchyma was completely replaced by lymphoma cells, whereas there were 
multiple small foci of perivascular lymphoma cell infiltration in the liver and lung. 
Scale bars, 200 µm. 
 
Fig. 4. Characterization of mouse embryonic fibroblasts (MEFs) and MEF-derived 
cell lines isolated from mito-miceND6M. 
(A) Numbers of cell divisions of MEF lines required for immortalization; Av., 
average number of cell divisions. Data are represented as mean values with SD (n 
= 3). *P < 0.05 compared with control B6 mice. (B) Transformation frequencies of 
immortalized MEF (3T3) lines to express tumorigenicity. (C) Tumor growth of the 
transformed 3T3 (fibrosarcoma) lines isolated from tumor masses formed (see Fig. 
23 
4B). Data are represented as mean values with SD (n = 3). (D) Identification of 
mtDNA genotypes of transformed 3T3 (fibrosarcoma) lines. The G13997A mtDNA 
in FSND6M-I and -III produced 114- and 33-bp fragments owing to the gain of an 
Afl II site by the G13997A substitution in the ND6 gene, whereas B6 mtDNA 
without the mutation in FSB6-II and -III produced uncut 147-bp fragments. (E) 
Metastatic potentials of the transformed 3T3 lines (i.e., fibrosarcoma lines). Data 
are represented as mean values with SD (n = 3). *P < 0.05 compared with two B6 
fibrosarcoma lines. 




Table 1.  Frequencies of lymphoma in dead or moribund mice
Mouse strain Spleen Liver Lung
Lymph
node HE CD45 B220 CD3 FL DLBCL
Mito-mice ND6M 35 16
  ( ND6M – 31 ) 29 + + Lymphoma + + – B cell – +
  ( ND6M – 29 ) 28 + Lymphoma + + – B cell – +
  ( ND6M – 28 ) 28 + Lymphoma + + – B cell – +
  ( ND6M – 27 ) 28 + + Lymphoma + + – B cell + –
  ( ND6M – 23 ) 26 + + Lymphoma + + – B cell – +
  ( ND6M – 20 ) 25 + Lymphoma + + – B cell – +
  ( ND6M – 18 ) 24 + + Lymphoma + + – B cell + –
  ( ND6M – 13 ) 23 + + Lymphoma + – + T cell – –
  ( ND6M – 11 ) 22 + + Lymphoma + + – B cell – +
  ( ND6M – 7 ) 19 + Lymphoma + + – B cell – +
  ( ND6M – 6 ) 18 + + + Lymphoma + + – B cell – +
  ( ND6M – 5 ) 18 + Lymphoma + + – B cell – +
  ( ND6M – 4 ) 16 + + + Lymphoma + + – B cell + –
  ( ND6M – 3 ) 12 + Lymphoma + + – B cell – +
  ( ND6M – 2 ) 12 + + Lymphoma + + – B cell – +
  ( ND6M – 1 ) 10 + + Lymphoma + + – B cell + –
B6 35 3
  ( B6 – 34 ) 33 + Lymphoma + + – B cell – +
  ( B6 – 14 ) 25 + Lymphoma + + – B cell – +
  ( B6 – 1 ) 12 + + Lymphoma + – + T cell – –
Mito-mice COIM 18 1
  ( COIM – 11 ) 27 + Lymphoma + + – B cell – +
 DLBCL, diffuse large B-cell lymphoma;  FL, follicular lymphoma
Cell type
* Individual codes were allocated in order of death.
†　In most cases, the spleen was the primary B-lymphoma site and the liver and lung were involved secondarily by hematogeneous metastasis (spread), because
most of the splenic parenchyma was completely replaced by lymphoma cells, whereas there were multiple small foci of perivascular lymphoma cell infiltration in
the liver and lung (see Fig. 3B). In some cases where tumors were present only in the liver or lung, they were not hepatomas or lung carcinomas, but instead were
lymphomas that had spread from the spleen or from lymph nodes near the organs, because all stained positively for CD45 and B220 or CD3.
No. of dead
mice
No. of dead mice
with tumors
(individual code*)
Lifespan
(months)
Tissue with tumor Histological analyses†
Cell
lineage
